Literature DB >> 7811739

Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types.

A K van Vliet1, G C van Thiel, R H Huisman, H Moshage, S H Yap, L H Cohen.   

Abstract

The three vastatins examined, lovastatin, simvastatin and pravastatin, are equally strong inhibitors of the sterol synthesis in human hepatocytes in culture with IC50-values of 4.1, 8.0 and 2.0 nM, respectively. However, in the human extrahepatic cells: umbilical vascular endothelial cells, retinal pigment epithelial cells, cornea fibroblasts and granulosa cells, pravastatin was much less inhibiting the sterol synthesis than lovastatin or simvastatin. It was observed as well that longer incubation with the vastatins resulted in higher IC50-values. In order to show that the feedback regulation mechanism for 3-hydroxy-3-methylglutaryl-coenzyme A reductase was involved in this phenomena mRNA levels were measured in human vascular endothelial cells after incubation with the vastatins for 3.5 h and for 20 h. Indeed, lovastatin and simvastatin gave rise to higher levels of HMG-CoA reductase mRNA after 20 h than after 3.5 h of incubation. The differences observed in different human cell types can be explained by supposing that pravastatin is transported into the human hepatocyte via a liver-specific transporter. This was supported by the results of uptake experiments with 14C-labelled pravastatin and 14C-labelled simvastatin into human hepatocytes compared to that into human umbilical endothelial cells (as an example of an extrahepatic cell type). [14C]-Simvastatin was associated with both cell types, whereas [14C]-pravastatin was hardly associated with human endothelial cells, but to a similar extent as [14C]-simvastatin with human hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7811739     DOI: 10.1016/0005-2760(94)00176-y

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin.

Authors:  T Hatanaka; S Honda; S Sasaki; K Katayama; T Koizumi
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

Review 2.  The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.

Authors:  C Sarti; M Kaarisalo; J Tuomilehto
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

3.  Statins inhibit blastocyst formation by preventing geranylgeranylation.

Authors:  Vernadeth B Alarcon; Yusuke Marikawa
Journal:  Mol Hum Reprod       Date:  2016-02-07       Impact factor: 4.025

Review 4.  Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention.

Authors:  Kirsten Lawrence Cleary; Kelly Roney; Maged Costantine
Journal:  Semin Perinatol       Date:  2014-10-12       Impact factor: 3.300

5.  Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations.

Authors:  Niek C A van de Pas; Johan A C Rullmann; Ruud A Woutersen; Ben van Ommen; Ivonne M C M Rietjens; Albert A de Graaf
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-09       Impact factor: 2.745

6.  Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.

Authors:  T Tokui; D Nakai; R Nakagomi; H Yawo; T Abe; Y Sugiyama
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

Review 7.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

8.  Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells.

Authors:  M Ohtawa; N Masuda; I Akasaka; A Nakashima; K Ochiai; M Moriyasu
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

9.  Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain.

Authors:  Neelima B Chauhan; George J Siegel; Douglas L Feinstein
Journal:  Neurochem Res       Date:  2004-10       Impact factor: 3.996

10.  Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells.

Authors:  K Gauthaman; N Manasi; A Bongso
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.